Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902625 | 0.85 | RXRA (0.44) | RXRANR1H2NR1H3KDM4EHPGD | |
| SCHEMBL4897578 | 0.78 | RXRA (0.53) | RXRANR1H2NR1H3KDM4EHPGD | |
| SCHEMBL2387622 | 0.77 | RXRA (0.61) | RXRANR1H2NR1H3KDM4EHPGD | |
| SCHEMBL2266726 | 0.76 | NR1H2 (0.65) | RXRANR1H2NR1H3KDM4EHPGD | |
| SCHEMBL2263662 | 0.76 | RXRA (0.62) | RXRANR1H2NR1H3MAPT | |
| SCHEMBL4897266 | 0.75 | RXRA (0.49) | RXRANR1H2NR1H3KDM4EHPGD | |
| SCHEMBL4899595 | 0.75 | RXRA (0.42) | RXRANR1H2NR1H3KDM4EMAPT | |
| SCHEMBL4902632 | 0.75 | RXRA (0.46) | RXRANR1H2NR1H3MAPTALDH1A1 | |
| SCHEMBL2387472 | 0.75 | RXRA (0.49) | RXRANR1H2NR1H3KDM4EHPGD | |
| SCHEMBL2268061 | 0.75 | NR1H2 (0.61) | RXRANR1H2NR1H3KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.